Kortuc Inc. develops cancer radiotherapy solutions, specifically offering an innovative radiosensitizer designed to eliminate tumor hypoxia and maximize the effectiveness of radiation treatment. The company serves the medical and oncology research sectors by advancing clinical trials and expanding treatment options for cancer patients.
Subscribe to see KORTUC USA INC.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
KORTUC USA INC. is a biotechnology company headquartered in United States. Its most recent funding round raised $108.7M in April 2023. Xcout tracks 2 named people at KORTUC USA INC., including Kazu Matsuda (Chief Executive Officer).
As of 16 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $108.7M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of KORTUC USA INC.'s closest competitors — see the full list of competitors and alternatives →
Haniva Technology LLC is a biotechnology company that develops patented combination therapies and drug delivery devices to treat various forms of cancer. Its research focuses on using non-thermal plasma alongside hypoxia-activated DNA-damaging agents to selectively target and reduce tumor volume, prevent metastasis, and serve as an adjuvant treatment following tumor resection.
KAIO Therapy, LLC develops an Immune Activating Heat Therapy (IAHT) technology designed to treat cancer patients by combining hyperthermia with immunotherapy. The system utilizes injected nanoparticles and an alternating magnetic field device to induce controlled heat within tumors, which destroys cancer cells and activates the patient's immune system against primary and metastatic tumors.
CRISM Therapeutics Corporation is dedicated to developing innovative drug delivery systems that enhance the effectiveness of cancer medications targeting solid tumors. Their primary offering, ChemoSeed, is designed for direct insertion into a tumor or the surgical site post-tumor removal, ensuring that therapeutic concentrations of chemotherapy agents are precisely localized to the cancerous tissue. This technology finds particular application in treating gliomas, a form of brain tumor. The company was established in 2016 and is headquartered in Road Town, British Virgin Islands.
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development of therapies using Tumor Treating Fields.
Nobilis Therapeutics, Inc. is a Delaware C-corporation headquartered in Portland, Oregon, focused on the therapeutic uses of inert gas mixtures and portable delivery devices.
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about KORTUC USA INC.? Suggest a correction · Work at KORTUC USA INC.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.